+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-09-28Number of Pages: 155

Intravenous Immunoglobulin (IVIG) Market (Indication - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Humoral Immunodeficiency, Idiopathic Thrombocytopenic Purpura (ITP), Guillain-Barre Syndrome, Myasthenia Gravis, Multifocal Motor Neuropathy (MMN), Kawasaki Disease, Hypogammaglobulinemia, and Chronic Lymphocytic Leukemia; End User - Hospitals, Clinics, and Home Care) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Global Intravenous Immunoglobulin (IVIG) Market: Snapshot

The global market for intravenous immunoglobulin (IVIG) products and therapies is heading in a positive direction due to several innovative techniques and advantages it offers to clinicians worldwide. The market is expected to expand at a healthy pace in the near future. Factors that will support market’s growth include technological improvements in the methods used for production and purification of IVIG products and an improving health care infrastructure across the globe. The rising patient pool suffering from immunological and neurological disorders, mounting geriatric population, and rising production of IVIG products are also expected to have a significant positive impact on market’s future growth prospects.

Transparency Market Research estimates that the market will exhibit a healthy 8.5% CAGR over the period between 2016 and 2024. Expanding at this pace, the market, which valued at US$7.23 bn in 2015, is expected to reach US$14.92 bn in 2024. 

intravenous immunoglobulin market

Hospitals to Retain Dominance but Lose Promise to Home Care

In terms of end users of IVIG infusion therapy and products, the global IVIG market is segmented into hospitals, clinics, and home care settings. Of these, the hospitals segment is presently the dominant end user of the intravenous immunoglobulin (IVIG) market. A continuous rise in the number of patients opting for hospitals rather than clinics is the major driver of the hospitals segment. High budgetary expenditure, rising government investment, and better reimbursement policies also augment the number of patients opting hospitals for intravenous immunoglobulin (IVIG) therapies. 

IVIG infusion therapy is a time consuming procedure, in which the infusion takes place at a slow rate and lasts for a long period of time. This factor is also expected to increase consumer preference to home care settings for treatment. Although the hospitals segment will continue to lead the global IVIG market, the rising inclination to home care is expected to make home care the most lucrative end-user segment of the intravenous immunoglobulin (IVIG) market over the forecast. 

Market in North America to Continue to Remain Highly Lucrative

North America is presently the dominant regional market for intravenous immunoglobulin (IVIG) and is likely to witness significant growth during the forecast period as well. In the U.S., North America’s most lucrative IVIG market, the demand for IVIG infusion therapy is driven by the country’s strong economy, advancements in technology, abundant plasma supply, and rising prevalence of immunological disorders. Other factors ascribable to market growth include the favorable reimbursement policies, high investments in research and development, and increasing geriatric population in the country.

FDA’s approval for payments to plasma donors to encourage plasma donation and boost yield is another major factor driving the IVIG market in the U.S. This has helped the country to not only become self-sufficient in plasma supply, but also a major exporter of plasma derived products globally, consecutively strengthening the North America market.

The IVIG market in Europe is also witnessing strong growth owing to increasing patient pool and geriatric population. Higher acceptance of innovative technologies and launch of new products in the region are also driving the IVIG market. Additionally, the ongoing clinical development of new products is anticipated to boost market growth during the forecast period. Asia Pacific is expected to be a promising market for intravenous immunoglobulin (IVIG) due to developing economies and presence of large underserved patient population. The number of patients suffering from immunological diseases is also high in the region, naturally increasing the demand for intravenous immunoglobulin products and therapies.

Some of the key vendors operating in the highly consolidated global IVIG market are Baxalta Incorporated, Biotest AG, CSL Behring LLC, China Biologic Products, Inc., Grifols S.A., LFB Biomedicaments S.A., Kedrion S.p.A., Octapharma AG, and Sanquin Plasma Products B.V.

Section 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Intravenous Immunoglobulin (IVIG): Market Snapshot
3.2 Market Share Analysis by Region, 2015
3.3 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Map

Section 4 Market Overview
4.1 Indication Overview
4.2 Global Intravenous Immunoglobulin (IVIG) Market: Key Industry Developments
4.3 Global Intravenous Immunoglobulin (IVIG) Market: Market Indicators

Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
      5.2.1 Rise in prevalence of autoimmune disorders
      5.2.2 Increase in global geriatric population
      5.2.3 Growing usage in off-label indications
      5.2.4 Improved technology for production and purification methods
      5.2.5 Favorable government initiatives and approvals
      5.2.6 Increase in health care spending & improving health care infrastructure
      5.2.7 Rise in incidence of hematological, neurological disorders
5.3 Restraints
      5.3.1 High cost of treatment
      5.3.2 Chronic side effects
      5.3.3 Supply demand gaps
      5.3.4 Alternate therapies such as subcutaneous infusion IG (SCIG) and recombinant Indications
5.4 Global Intravenous Immunoglobulin (IVIG) Market: Opportunity Analysis
5.5 Opportunities
      5.5.1 Application in newer indications
      5.5.2 Increasing global plasma yield to offer significant opportunities to new entrants
5.6 Key Trends
5.7 Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
5.8 Value Chain Analysis
5.9 Intravenous Immunoglobulin (IVIG) Market Outlook

Section 6 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication
6.1 Key Findings
6.2 Introduction
6.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication
6.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by Indication 
      6.4.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      6.4.2 Primary Humoral Immunodeficiency 
      6.4.3 Idiopathic Thrombocytopenic Purpura (ITP)
      6.4.4 Guillain-Barre Syndrome
      6.4.5 Myasthenia Gravis
      6.4.6 Multifocal Motor Neuropathy (MMN)
      6.4.7 Kawasaki Disease
      6.4.8 Hypogammaglobulinemia
      6.4.9 Chronic Lymphocytic Leukemia
      6.4.10 Others
6.5 Market Attractiveness Analysis, by Indication
6.6 Key Trends

Section 7 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
7.1 Key Findings
7.2 Introduction
7.3 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user
7.4 Intravenous Immunoglobulin (IVIG) Market Analysis, by End-user
      7.4.1 Hospitals
      7.4.2 Clinics
      7.4.3 Home Care
7.5 Market Attractiveness Analysis, by End-user
7.6 Key Trends

Section 8 Intravenous Immunoglobulin (IVIG) Market Analysis, by Region
8.1 Global Intravenous Immunoglobulin (IVIG) Market Snapshot, by Country
8.2 Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region
8.3 Intravenous Immunoglobulin (IVIG) Market Forecast, by Region
8.4 Market Attractiveness Analysis, by Region

Section 9 North America Intravenous Immunoglobulin (IVIG) Market Analysis
9.1 Key Findings
9.2 Market Overview
9.3 Market Analysis, by Indication      
      9.3.1 Market Value Share Analysis, by Indication
      9.3.2 Market Size (US$ Mn) Forecast, by Indication
               9.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               9.3.2.2 Primary Humoral Immunodeficiency 
               9.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               9.3.2.4 Guillain-Barre Syndrome
               9.3.2.5 Myasthenia Gravis
               9.3.2.6 Multifocal Motor Neuropathy (MMN)
               9.3.2.7 Kawasaki Disease
               9.3.2.8 Hypogammaglobulinemia
               9.3.2.9 Chronic Lymphocytic Leukemia
               9.3.2.10 Others
9.4 Market Analysis, by End-user
      9.4.1 Market Value Share Analysis, by End-user
      9.4.2 Market Size (US$ Mn) Forecast, by End-user
               9.4.2.1 Hospitals
               9.4.2.2 Clinics
               9.4.2.3 Home Care
9.5 Market Analysis, by Country
      9.5.1 Market Value Share Analysis, by Country
      9.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               9.5.2.1 U.S.
               9.5.2.2 Canada
9.6 Market Attractiveness Analysis
      9.6.1 by Indication 
      9.6.2 by End-user
      9.6.3 by Country

Section 10 Europe Intravenous Immunoglobulin (IVIG) Market Analysis
10.1 Key Findings
10.2 Market Overview
10.3 Market Analysis, by Indication
      10.3.1 Market Value Share Analysis, by Indication
      10.3.2 Market Size (US$ Mn) Forecast, by Indication
               10.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               10.3.2.2 Primary Humoral Immunodeficiency 
               10.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               10.3.2.4 Guillain-Barre Syndrome
               10.3.2.5 Myasthenia Gravis
               10.3.2.6 Multifocal Motor Neuropathy (MMN)
               10.3.2.7 Kawasaki Disease
               10.3.2.8 Hypogammaglobulinemia
               10.3.2.9 Chronic Lymphocytic Leukemia
               10.3.2.10 Others
10.4 Market Analysis, by End-user
      10.4.1 Market Value Share Analysis, by End-user
      10.4.2 Market Size (US$ Mn) Forecast, by End-user
               10.4.2.1 Hospitals
               10.4.2.2 Clinics
               10.4.2.3 Home Care
10.5 Market Analysis, by Country
      10.5.1 Market Value Share Analysis, by Country
      10.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               10.5.2.1 U.K.
               10.5.2.2 Germany
               10.5.2.3 France
               10.5.2.4 Spain
               10.5.2.5 Italy
               10.5.2.6 Rest of Europe
10.6 Market Attractiveness Analysis
      10.6.1 by Indication 
      10.6.2 by End-user
      10.6.3 by Country

Section 11 Asia Pacific Intravenous Immunoglobulin (IVIG) Market Analysis
11.1 Key Findings
11.2 Market Overview
11.3 Market Analysis, by Indication
      11.3.1 Market Value Share Analysis, by Indication
      11.3.2 Market Size (US$ Mn) Forecast, by Indication
               11.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               11.3.2.2 Primary Humoral Immunodeficiency 
               11.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               11.3.2.4 Guillain-Barre Syndrome
               11.3.2.5 Myasthenia Gravis
               11.3.2.6 Multifocal Motor Neuropathy (MMN)
               11.3.2.7 Kawasaki Disease
               11.3.2.8 Hypogammaglobulinemia
               11.3.2.9 Chronic Lymphocytic Leukemia
               11.3.2.10 Others
11.4 Market Analysis, by End-user
      11.4.1 Market Value Share Analysis, by End-user
      11.4.2 Market Size (US$ Mn) Forecast, by End-user
               11.4.2.1 Hospitals
               11.4.2.2 Clinics
               11.4.2.3 Home Care
11.5 Market Analysis, by Country
      11.5.1 Market Value Share Analysis, by Country
      11.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               11.5.2.1 China
               11.5.2.2 Japan
               11.5.2.3 Australia
               11.5.2.4 India
               11.5.2.5 Rest of Asia Pacific
11.6 Market Attractiveness Analysis
      11.6.1 by Indication 
      11.6.2 by End-user
      11.6.3 by Country

Section 12 Latin America Intravenous Immunoglobulin (IVIG) Market Analysis
12.1 Key Findings
12.2 Market Overview
12.3 Market Analysis, by Indication
      12.3.1 Market Value Share Analysis, by Indication
      12.3.2 Market Size (US$ Mn) Forecast, by Indication
               12.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               12.3.2.2 Primary Humoral Immunodeficiency 
               12.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               12.3.2.4 Guillain-Barre Syndrome
               12.3.2.5 Myasthenia Gravis
               12.3.2.6 Multifocal Motor Neuropathy (MMN)
               12.3.2.7 Kawasaki Disease
               12.3.2.8 Hypogammaglobulinemia
               12.3.2.9 Chronic Lymphocytic Leukemia
               12.3.2.10 Others
12.4 Market Analysis, by End-user
      12.4.1 Market Value Share Analysis, by End-user
      12.4.2 Market Size (US$ Mn) Forecast, by End-user
               12.4.2.1 Hospitals
               12.4.2.2 Clinics
               12.4.2.3 Home Care
               12.5 Market Analysis, by Country
      12.5.1 Market Value Share Analysis, by Country
      12.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               12.5.2.1 Brazil
               12.5.2.2 Mexico
               12.5.2.3 Rest of LATAM
12.6 Market Attractiveness Analysis
      12.6.1 by Indication 
      12.6.2 by End-user
      12.6.3 by Country

Section 13 Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Analysis
13.1 Key Findings
13.2 Market Overview
13.3 Market Analysis, by Indication
      13.3.1 Market Value Share Analysis, by Indication
      13.3.2 Market Size (US$ Mn) Forecast, by Indication
               13.3.2.1 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
               13.3.2.2 Primary Humoral Immunodeficiency 
               13.3.2.3 Idiopathic Thrombocytopenic Purpura (ITP)
               13.3.2.4 Guillain-Barre Syndrome
               13.3.2.5 Myasthenia Gravis
               13.3.2.6 Multifocal Motor Neuropathy (MMN)
               13.3.2.7 Kawasaki Disease
               13.3.2.8 Hypogammaglobulinemia
               13.3.2.9 Chronic Lymphocytic Leukemia
               13.3.2.10 Others
13.4 Market Analysis, by End-user
      13.4.1 Market Value Share Analysis, by End-user
      13.4.2 Market Size (US$ Mn) Forecast, by End-user
               13.4.2.1 Hospitals
               13.4.2.2 Clinics
               13.4.2.3 Home Care
13.5 Market Analysis, by Country
      13.5.1 Market Value Share Analysis, by Country
      13.5.2 Market Size (US$ Mn) Forecast, by Country, 2016–2024
               13.5.2.1 South Africa
               13.5.2.2 Saudi Arabia
               13.5.2.3 Rest of MEA
13.6 Market Attractiveness Analysis
      13.6.1 by Indication 
      13.6.2 by End-user
      13.6.3 by Country

Section 14 Company Profiles
14.1 Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)
14.2 Competition Matrix
14.3 Company Profiles
      14.3.1 Baxalta Incorporated
               14.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.1.2 Financial Overview
               14.3.1.3 Product Portfolio
               14.3.1.4 SWOT Analysis
               14.3.1.5 Strategic Overview
      14.3.2 Biotest AG
               14.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.2.2 Financial Overview
               14.3.2.3 Product Portfolio
               14.3.2.4 SWOT Analysis
               14.3.2.5 Strategic Overview
      14.3.3 China Biologic Products, Inc.
               14.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.3.2 Financial Overview
               14.3.3.3 Product Portfolio
               14.3.3.4 SWOT Analysis
               14.3.3.5 Strategic Overview
      14.3.4 CSL Behring LLC
               14.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.4.2 Financial Overview
               14.3.4.3 Product Portfolio
               14.3.4.4 SWOT Analysis
               14.3.4.5 Strategic Overview
      14.3.5 Grifols S.A.
               14.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.5.2 Financial Overview
               14.3.5.3 Product Portfolio
               14.3.5.4 SWOT Analysis
               14.3.5.5 Strategic Overview
      14.3.6 Kedrion S.p.A.
               14.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.6.2 Financial Overview
               14.3.6.3 Product Portfolio
               14.3.6.4 SWOT Analysis
               14.3.6.5 Strategic Overview
      14.3.7 LFB Biomedicaments S.A.
               14.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.7.2 Financial Overview
               14.3.7.3 Product Portfolio
               14.3.7.4 SWOT Analysis
               14.3.7.5 Strategic Overview
      14.3.8 Octapharma AG
               14.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.8.2 Financial Overview
               14.3.8.3 Product Portfolio
               14.3.8.4 SWOT Analysis
               14.3.8.5 Strategic Overview
      14.3.9 Sanquin Plasma Products B.V.
               14.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
               14.3.9.2 Financial Overview
               14.3.9.3 Product Portfolio
               14.3.9.4 SWOT Analysis
               14.3.9.5 Strategic Overview

List of Figures

Figure 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 02: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Indication, 2016 and 2024
Figure 03: Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Revenue, US$ Mn, 2014–2024
Figure 04: Global Primary Humoral Immunodeficiency Market Revenue, US$ Mn, 2014–2024
Figure 05: Global Idiopathic Thrombocytopenic Purpura (ITP) Market Revenue, US$ Mn, 2014–2024
Figure 06: Global Guillain-Barre Syndrome Market Revenue, US$ Mn, 2014–2024
Figure 07: Global Myasthenia Gravis Market Revenue, US$ Mn, 2014–2024
Figure 08: Global Multifocal Motor Neuropathy (MMN) Market Revenue, US$ Mn, 2014–2024
Figure 09: Global Kawasaki Disease Market Revenue, US$ Mn, 2014–2024
Figure 10: Global Hypogammaglobulinemia Market Revenue, US$ Mn, 2014–2024
Figure 11: Global Chronic Lymphocytic Leukemia Market Revenue, US$ Mn, 2014–2024
Figure 12: Global Other Indications Market Revenue, US$ Mn, 2014–2024
Figure 13: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Indication
Figure 14: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by End-user, 2016 and 2024
Figure 15: Global Hospitals Market Revenue, US$ Mn, 
Figure 16: Global Clinics Market Revenue, US$ Mn,
Figure 17: Global home care Market Revenue, US$ Mn, 2014–2024
Figure 18: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by End-user
Figure 19: Global Intravenous Immunoglobulin (IVIG) Market Value Share Analysis, by Region, 2016 and 2024
Figure 20: Intravenous Immunoglobulin (IVIG) Market Attractiveness Analysis, by Region
Figure 21: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
Figure 22: North America Market Attractiveness Analysis, by Country
Figure 23: North America Market Value Share Analysis, by Indication, 2016 and 2024
Figure 24: North America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 25: North America Market Value Share Analysis, by Country, 2016 and 2024
Figure 26: North America Market Attractiveness Analysis, by Indication 
Figure 27: North America Market Attractiveness Analysis, by End-user
Figure 28: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2016–2024
Figure 29: Europe Market Attractiveness Analysis, by Country
Figure 30: Europe Market Value Share Analysis, by Indication, 2016 and 2024
Figure 31: Europe Market Value Share Analysis, by End-user, 2016 and 2024
Figure 32: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 33: Europe Market Attractiveness Analysis, by Indication
Figure 34: Europe Market Attractiveness Analysis, by End-user
Figure 35: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 36: Asia Pacific Market Attractiveness Analysis, by Country
Figure 37: Asia Pacific Market Value Share Analysis, by Indication, 2016 and 2024
Figure 38: Asia Pacific Market Value Share Analysis, by End-user, 2016 and 2024
Figure 39: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 40: Asia Pacific Market Attractiveness Analysis, by Indication
Figure 41: Asia Pacific Market Attractiveness Analysis, by End-user
Figure 42: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 43: Latin America Market Attractiveness Analysis, by Country
Figure 44: Latin America Market Value Share Analysis, by Indication, 2016 and 2024
Figure 45: Latin America Market Value Share Analysis, by End-user, 2016 and 2024
Figure 46: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 47: Latin America Market Attractiveness Analysis, by Indication
Figure 48: Latin America Market Attractiveness Analysis, by End-user
Figure 49: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, 2014–2024
Figure 50: Middle East & Africa Market Attractiveness Analysis, by Country
Figure 51: Middle East & Africa Market Value Share Analysis, by Indication, 2016 and 2024
Figure 52: Middle East & Africa Market Value Share Analysis, by End-user, 2016 and 2024
Figure 53: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 54: Middle East & Africa Market Attractiveness Analysis, by Indication
Figure 55: Middle East & Africa Market Attractiveness Analysis, by End-user
Figure 56: Global Intravenous Immunoglobulin (IVIG) Market Share Analysis, by Company (2015)

List of Tables

Table 01: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 02: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 03: Global Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 04: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 05: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 06: North America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 07: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 08: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 09: Europe Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 10: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 11: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2016–2024
Table 12: Asia Pacific Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 13: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication, 2014–2024
Table 14: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 15: Latin America Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 16: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Indication Type, 2014–2024
Table 17: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by End-user, 2014–2024
Table 18: Middle East & Africa Intravenous Immunoglobulin (IVIG) Market Size (US$ Mn) Forecast, by Country, 2014–2024

Intravenous Immunoglobulin (IVIG) Market: Scope and Methodology

This report on the global intravenous immunoglobulin (IVIG) market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. Primary research formed the bulk of our research efforts along with information collected from telephonic interviews and interactions via e-mails. Secondary research involved study of company websites, annual reports, press releases, stock analysis presentations, and various international and national databases. The report provides market size in terms of US$ Mn for each segment for the period from 2014 to 2024, considering the macro and micro environmental factors. Growth rates for each segment within the global intravenous immunoglobulin (IVIG) market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, and regulatory requirements. 

A detailed qualitative analysis of factors responsible for driving and restraining market growth and future opportunities has been provided in the market overview section. This section of the report also provide insights into the key trends of the intravenous immunoglobulin (IVIG) market such as shift from intravenous to subcutaneous infusion of immunoglobulin. The key market indicators influencing global intravenous immunoglobulin (IVIG) market taken into consideration include prevalence of immunological disorders, global blood and plasma yield and geriatric population. The report also includes market attractiveness analysis of the major segments that provides a thorough analysis of the overall competitive scenario in the global intravenous immunoglobulin (IVIG) market. The report also highlights key events of the global intravenous immunoglobulin industry. A value chain analysis along with list of major players, hospitals and distributors is also included in the report.

Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. The year on year growth of global intravenous immunoglobulin (IVIG) market for each segment is also reflected. Additionally, market related factors such as increasing preference for product innovation, and growing number of acute and chronic patients in various geographies and historical year-on-year growth have been taken into consideration while estimating the market size.

Intravenous Immunoglobulin (IVIG) Market: Segmentation

Based on indication, the global intravenous immunoglobulin (IVIG) market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), primary humoral immunodeficiency, idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, myasthenia gravis, multifocal motor neuropathy (MMN), Kawasaki disease, hypogammaglobulinemia, chronic lymphocytic leukemia, and others. Based on end-user, the market has been segmented into hospitals, clinics, and home care. Hospitals segment is expected to remain dominant during the forecast period. However, home care segment is expected to grow at a higher CAGR than others.

Geographically, the global intravenous immunoglobulin (IVIG) market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented into major countries from each region. These include the U.S., Canada, the U.K., Germany, France, Italy, Spain, China, Australia, India, Japan, Brazil, and Mexico.

Intravenous Immunoglobulin (IVIG) Market: Competitive Landscape

The report also profiles major players in the intravenous immunoglobulin (IVIG) market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. A thorough market share analysis of major companies operating in the intravenous immunoglobulin (IVIG) market is provided in the report. The report also includes a competition matrix that provides insights into recent developments and activities done by the major market players. Key companies profiled in the report include Baxalta Incorporated, Biotest AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., LFB Biomedicaments S.A., Octapharma AG, and Sanquin Plasma Products B.V.

The global intravenous immunoglobulin (IVIG) market has been segmented as follows:

Global Intravenous immunoglobulin (IVIG) Market, by Indication

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Primary Humoral Immunodeficiency
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Guillain-Barre Syndrome
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy (MMN)
  • Kawasaki Disease
  • Hypogammaglobulinemia
  • Chronic Lymphocytic Leukemia
  • Others

Global Intravenous immunoglobulin (IVIG) Market, by End-user

  • Hospitals
  • Clinics
  • Home Care

Global Intravenous immunoglobulin (IVIG) Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • Australia
    • India
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa


 
 
Back To Top